Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient

被引:49
作者
Niu, Peihua [1 ]
Zhang, Senyan [2 ]
Zhou, Panpan [2 ]
Huang, Baoying [1 ]
Deng, Yao [1 ]
Qin, Kun [1 ]
Wang, Pengfei [2 ]
Wang, Wenling [1 ]
Wang, Xinquan [2 ]
Zhou, Jianfang [1 ]
Zhang, Linqi [2 ]
Tan, Wenjie [1 ]
机构
[1] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, MOH Key Lab Med Virol, Beijing, Peoples R China
[2] Tsinghua Univ, Beijing Adv Innovat Ctr Struct Biol, Sch Life Sci, Minist Educ,Key Lab Prot Sci,Collaborat Innovat C, Beijing, Peoples R China
关键词
crystallographic analysis; human monoclonal antibody; MERS-CoV; neutralizing antibody repertoires; HUMAN MONOCLONAL-ANTIBODIES; RECEPTOR-BINDING DOMAIN; MERS-COV; SPIKE PROTEIN; SAUDI-ARABIA; POSTEXPOSURE EFFICACY; DETERMINANTS; EVOLUTION; SOFTWARE; ANTIGEN;
D O I
10.1093/infdis/jiy311
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory infection with a high (similar to 35%) mortality rate. Neutralizing antibodies targeting the spike of MERS-CoV have been shown to be a therapeutic option for treatment of lethal disease. Methods. We describe the germline diversity and neutralizing activity of 13 potent human monoclonal antibodies (mAbs) that target the MERS-CoV spike (S) protein. Biological functions were assessed by live MERS-CoV, pseudotype particle and its variants, and structural basis was also determined by crystallographic analysis. Results. Of the 13 mAbs displaying strong neutralizing activity against MERS-CoV, two with the immunoglobulin heavy-chain variable region (IGHV) 1-69-derived heavy chain (named MERS-GD27 and MERS-GD33) showed the most potent neutralizing activity against pseudotyped and live MERS-CoV in vitro. Mutagenesis analysis suggested that MERS-GD27 and MERS-GD33 recognized distinct regions in S glycoproteins, and the combination of 2 mAbs demonstrated a synergistic effect in neutralization against pseudotyped MERS-CoV. The structural basis of MERS-GD27 neutralization and recognition revealed that its epitope almost completely overlapped with the receptor-binding site. Conclusions. Our data provide new insights into the specific antibody repertoires and the molecular determinants of neutralization during natural MERS-CoV infection in humans. This finding supports additional efforts to design and develop novel therapies to combat MERS-CoV infections in humans.
引用
收藏
页码:1249 / 1260
页数:12
相关论文
共 42 条
[1]   PHENIX:: building new software for automated crystallographic structure determination [J].
Adams, PD ;
Grosse-Kunstleve, RW ;
Hung, LW ;
Ioerger, TR ;
McCoy, AJ ;
Moriarty, NW ;
Read, RJ ;
Sacchettini, JC ;
Sauter, NK ;
Terwilliger, TC .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 :1948-1954
[2]  
Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
[3]   VH1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen [J].
Chan, CH ;
Hadlock, KG ;
Foung, SKH ;
Levy, S .
BLOOD, 2001, 97 (04) :1023-1026
[4]   Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset [J].
Chen, Zhe ;
Bao, Linlin ;
Chen, Cong ;
Zou, Tingting ;
Xue, Ying ;
Li, Fengdi ;
Lv, Qi ;
Gu, Songzhi ;
Gao, Xiaopan ;
Cui, Sheng ;
Wang, Jianmin ;
Qin, Chuan ;
Jin, Qi .
JOURNAL OF INFECTIOUS DISEASES, 2017, 215 (12) :1807-1815
[5]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[6]   Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method [J].
Chou, Ting-Chao .
CANCER RESEARCH, 2010, 70 (02) :440-446
[7]   Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome [J].
Corti, Davide ;
Passini, Nadia ;
Lanzavecchia, Antonio ;
Zambon, Maria .
JOURNAL OF INFECTION AND PUBLIC HEALTH, 2016, 9 (03) :231-235
[8]   Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus [J].
Corti, Davide ;
Zhao, Jincun ;
Pedotti, Mattia ;
Simonelli, Luca ;
Agnihothram, Sudhakar ;
Fett, Craig ;
Fernandez-Rodriguez, Blanca ;
Foglierini, Mathilde ;
Agatic, Gloria ;
Vanzetta, Fabrizia ;
Gopal, Robin ;
Langrish, Christopher J. ;
Barrettg, Nicholas A. ;
Sallusto, Federica ;
Baric, Ralph S. ;
Varani, Luca ;
Zambon, Maria ;
Perlman, Stanley ;
Lanzavecchia, Antonio .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (33) :10473-10478
[9]   Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study [J].
Cotten, Matthew ;
Watson, Simon J. ;
Kellam, Paul ;
Al-Rabeeah, Abdullah A. ;
Makhdoom, Hatem Q. ;
Assiri, Abdullah ;
Al-Tawfiq, Jaffar A. ;
Alhakeem, Rafat F. ;
Madani, Hossam ;
AlRabiah, Fahad A. ;
Al Hajjar, Sami ;
Al-Nassir, Wafa N. ;
Albarrak, Ali ;
Flemban, Hesham ;
Balkhy, Hanan H. ;
Alsubaie, Sarah ;
Palser, Anne L. ;
Gall, Astrid ;
Bashford-Rogers, Rachael ;
Rambaut, Andrew ;
Zumla, Alimuddin I. ;
Memish, Ziad A. .
LANCET, 2013, 382 (9909) :1993-2002
[10]   Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design [J].
Crowe, James E., Jr. .
CELL HOST & MICROBE, 2017, 22 (02) :193-206